IGF2 and carcinoma: Several studies on mouse models as well as human carcinomas demonstrated that altered high levels of IGF2 protein alone are not sufficient to trigger a tumorigenic transformation and that rather IGF2 LOI, a proposed constitutive risk biomarker for colorectal cancer [12, 13, 44, 45], and IGF2-DMR0 hypomethylation seem to be indicative for tumor susceptibility [15, 16, 48].